biotech

Europe is highlighted as having its own 'Biotech Star,' exemplified by Argenx's stock soaring following successful trials. Overall, the article notes that it has been a big week for biotech stocks on both sides of the Atlantic.

A new White House strategy has clarified military technology priorities, specifically highlighting undersea capabilities, outer space, and AI. Additionally, the National Security Science & Technology Strategy (NSSTS) outlined an array of secondary or longer-term technologies for consideration, including quantum and biotech.

Argenx SE's shares jumped after the European biotech reported a successful trial for its drug Vyvgart. The company reported that this was the latest large, successful trial conducted for the autoimmune drug.

The New Yorker article highlights China's aggressive push to dominate future industries like biotech, electric vehicles, and AI, attributing its success to state investment and U.S. policy gaps under Trump. China's advancements include leading global production in drones, EVs, and solar cells, while leveraging surveillance technologies and attracting Western talent.

Biotech firms are attracting significant dealmaking and investor interest, with 37 biotech acquisitions over $1 billion this year driven by pharma companies seeking to strengthen pipelines before patent expirations. The Trump administration’s regulatory approach and profits from top-selling drugs are fueling mergers, while biotech IPOs are outperforming AI-related listings.

The article discusses the end of GSK’s chronic cough treatment and highlights a gene therapy approach generating both excitement and skepticism. It also mentions Jennifer Doudna’s work on AI-designed gene editors and Kalshi’s expansion into biotech.

NITI Aayog proposes a ₹50,000 crore fund to boost India’s biotech sector through mission-mode execution, new financing, and regulatory reforms, aiming to expand the bioeconomy from $195.3 billion in 2025 to $2.6 trillion by 2047.

Reed Jobs focuses on advancing cancer cures through his venture firm Yosemite, which has grown from a new startup to a team of 17. The biotech industry faces patent expirations for blockbuster drugs, creating new opportunities, while AI has become a core part of Yosemite's operations. Jobs expressed surprise at the company's rapid progress.

Katie Stockton of Fairlead Strategies notes strong buying momentum in healthcare, industrial, biotech, insurance, and utility sectors amid slumping AI stocks, suggesting potential benefits for non-tech holdings.

Anthropic's CEO Dario Amodei revised his timeline for AI's impact on biotech, acknowledging that current AI tools may not yet enable the rapid progress he previously predicted. He cited limitations in model capabilities, the need for researchers to adapt to new tools, and slow infrastructure/regulatory changes as barriers. Anthropic introduced a biotech-focused product called Claude Science during an event.

Biotech stocks have surged in 2023, with the XBI index rising 30% year-to-date and hitting a five-year high. June saw a 19% gain for the XBI, bringing it close to its 2021 peak of $175.

Kardigan, a heart drug developer, is targeting a $1.4 billion valuation through its U.S. IPO. The company plans to raise up to $373.3 million by selling 23.3 million shares priced between $14 and $16 each.

GSK is in talks to acquire cancer biotech Nuvalent for more than $9 billion. The deal would rank as one of the UK drugmaker’s largest as biotech M&A activity accelerates this year.

A Miami biotech executive was followed into his skyscraper by a man accused of pushing him off the 25th floor, as shown in newly released surveillance video. Justin Zelin, 35, was seen entering the 47-story Akoya Condominium with Corey Hutterli, 37, on February 12.

Shares of French biotech Abivax fell 32% following updated trial data on its lead asset for bowel disease. The stock decline occurred after the company reported fresh data on its primary drug candidate.

China's growing influence in biotechnology has raised concerns among Western lawmakers and investors. US companies like Eli Lilly and Pfizer have formed partnerships with Chinese firms, sparking fears of over-reliance and potential geopolitical risks. Analysts compare China's biotech advantages to its dominance in the electric vehicle sector, citing factors like cost efficiency and supply chain integration.

Hong Kong-listed biotech company Insilico is reportedly exploring a potential listing in the United Arab Emirates, with Abu Dhabi mentioned as a possible location. The move could expand the company's financial reach and international presence.

Viktor Shvets from Macquarie Group predicts that the AI infrastructure investment bubble is unlikely to burst by 2026 or 2027, despite excessive spending on AI-related commodities and computing capacity. The bubble is expected to persist as various AI-related technologies including automation, quantum computing, and biotech continue to develop.

The outbreak of Hantavirus on a cruise ship has led to a surge in biotech and pharmaceutical stocks due to reports of firms developing vaccines. This increase is a result of potential treatments being developed. The Hantavirus outbreak is driving investment in these sectors.

Scientists have discovered a hidden universe of microbes inside coral reefs, each coral species supporting its own specialized microbial partners. These microbes produce a variety of chemical compounds with potential uses in medicine and biotech. The discovery highlights the importance of preserving coral reefs, which face growing threats.

Hemab, a biotech company backed by Novo, raised $301.5 million in an upsized IPO. The funding will support its focus on blood-related clinical research and development.

Hemab, a biotech company backed by Novo, is seeking to raise $212 million through a US IPO. The company is focused on medical research and development.

Aloe Blacc, a Grammy-nominated artist, faced challenges in biotech after attempting to fund COVID research despite being vaccinated. He discovered philanthropy lacks the structure to advance medical science, leading him to launch a pancreatic cancer drug platform.